Drug Trial Radar · NCT00855920
Study Utilizing Rilonacept in Gout Exacerbations
Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
225
Actual
Start
Mar 2009
Primary completion
Feb 2010
Study completion Feb 2010
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Mar 5, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days. Rilonacept alone was being compared with Indomethacin alone and the combination of Rilonacept plus Indomethacin in treating acute gout flares.
Conditions
- Acute Gout Flare
Interventions
RilonaceptDrug
Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
IndomethacinDrug
Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
Placebo (for Indomethacin)Other
Placebo (for Indomethacin) orally TID for 12 days.
Placebo (for Rilonacept)Other
Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 HoursTime frame: Pre-dose on Day 1 (Baseline); post-dose at 4, 8, 12, 24, 48, 72 hours and then daily up to Day 13 or until gout flare ends
Locations
44 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Huntsville, Alabama
Site not named
Mesa, Arizona
Site not named
Phoenix, Arizona
Site not named
Sierra Vista, Arizona
Site not named
Burbank, California
Site not named
Whittier, California
Site not named
Clearwater, Florida
Site not named
DeBary, Florida
Site not named
DeLand, Florida
Site not named
Jupiter, Florida
Site not named
Orange Park, Florida
Site not named
Orlando, Florida
Site not named
Oviedo, Florida
Site not named
Boise, Idaho
Site not named
Elizabethtown, Kentucky
Site not named
Baltimore, Maryland
Site not named
Wheaton, Maryland
Site not named
Detroit, Michigan
Site not named
Stevenville, Michigan
Site not named
Billings, Montana
Site not named
Albuquerque, New Mexico
Site not named
Albany, New York
Site not named
Burlington, North Carolina
Site not named
Cary, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Wilmington, North Carolina
Site not named
Willoughby Hills, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Lake Oswego, Oregon
Site not named
Portland, Oregon
Site not named
Johnstown, Pennsylvania
Site not named
Limerick, Pennsylvania
Site not named
Norristown, Pennsylvania
Site not named
Greenville, South Carolina
Site not named
Bristol, Tennessee
Site not named
Dallas, Texas
Site not named
Forth Worth, Texas
Site not named
Houston, Texas
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.